Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of joining.
- People whose general health and ability to carry out daily activities is rated at a good to fully active level (a score of 0 or 1 on a standard oncology scale).
- People who are expected to live for at least 12 weeks.
- People who have been diagnosed with relapsed or refractory classical Hodgkin lymphoma (a type of blood cancer that has come back or stopped responding to treatment), confirmed using standard 2014 diagnostic guidelines.
- People whose cancer has continued to grow or spread after receiving a type of immunotherapy drug that targets the PD-1 or PD-L1 pathway.
- People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements.
- People of reproductive potential who agree to use effective contraception from the start of the screening period until 120 days after the last dose of the study treatment.
Who may not be able to join:
- People diagnosed with a specific subtype of Hodgkin lymphoma called nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), or a related condition called gray zone lymphoma.
- People whose lymphoma has spread to the brain or spinal cord.
- People with a known history of a viral infection called HTLV-1 (human T-cell leukemia virus type 1).
- People who have had a stem cell transplant using their own cells, or a specialised immune cell therapy called CAR-T, within the 90 days before the first dose of the study treatment.
- People who have previously received a stem cell transplant or organ transplant from another person (a donor).
- People who have previously been treated with any therapy targeting certain immune pathways called CD47-SIRPα or LAG-3.
- People who have had another type of cancer within the 3 years before joining, or who still have signs of a cancer that was diagnosed more than 3 years ago.
- People who have had an active autoimmune disease (where the immune system attacks the body) requiring ongoing medical treatment within the past 2 years.
- People with a history of active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), or who have had this confirmed in the past.
- People who have had, or currently have, a lung condition called interstitial lung disease that has required steroid treatment.
- People with a known active Hepatitis B or Hepatitis C infection.
- People who still have unresolved side effects from previous cancer treatments.
- People with other serious health conditions that are not well controlled.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wenting Li, MD, Akeso
Phone: +86(0760)89873999
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase I: Number of participants with dose limiting toxicity (DLT); Phase I/II: Incidence and severity of adverse events (AEs); Phase I/II: Objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.